Inhibition of cyclooxygenase 2 synthesis suppresses Herpes simplex virus type 1 reactivation

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 2, 2005, Pages 114-120

  Gebhardt, Bryan M ^a   Varnell, Emily D ^a   Kaufman, Herbert E ^a  

^a LSU EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME SYNTHESIS; FEMALE; HEAT STRESS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HOMOGENATE; HYPERTHERMIA; IMMERSION; KERATITIS; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; TRIGEMINUS GANGLION; VIRUS INHIBITION; VIRUS REACTIVATION; VIRUS SHEDDING;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; HEAT STRESS DISORDERS; HERPESVIRUS 1, HUMAN; KERATITIS, HERPETIC; MICE; MICE, INBRED BALB C; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RECURRENCE; SULFONAMIDES; TRIGEMINAL GANGLION; VIRUS ACTIVATION;

EID: 17744381751     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.114     Document Type: Article

References (45)

1. Griffiths, P.D. Progress in the clinical management of herpesvirus infections. Antivir. Chem. Chemother. 6:191-209, 1995.
2. Liesegang, T.J. Ocular Herpes simplex infection: Pathogenesis and current therapy. Mayo Clin. Proc. 63: 1092-1105, 1988.
3. Beyer, C.F., Hill, J.M., and Kaufman, H.E. Antivirals and interferons. Ophthalmol. Clin. N. Am. 2:51-63, 1989.
4. Corey, L., Langenberg, A.G., Ashley, R., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. Chiron Vaccine Study Group. JAMA 282:331-340, 1999.
5. Stanberry, L.R., Spruance, S.L., Cunningham, A.L., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661, 2002.
6. De Clercq, E. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol 5:149-164, 1995.
7. Cassady, K.A., and Whitley, R.J. New therapeutic approaches to the alphaherpesvirus infections. J. Antimicrob. Chemother. 39:119-128, 1997.
8. Balfour Jr., H.H. Antiviral drugs. N. Engl. J. Med. 340:1255-1268, 1999.
9. Balzarini, J., Naesens, L., and De Clercq, E. New antivirals-mechanism of action and resistance development. Curr. Opin. Microbiol. 1:535-546, 1998.
10. Coen, D.M., and Schaffer, P.A. Antiherpesvirus drugs: A promising spectrum of new drugs and drug targets. Nature 2:278-288, 2003.
11. Brady, R.C., and Bernstein, D.I. Treatment of Herpes simplex virus infections. Antiviral Res. 61:73-81, 2004.
12. Wand, M., Gilbert, C.M., and Liesegang, T.J. Latanoprost and Herpes simplex keratitis. Am. J. Ophthalmol. 127:602-604, 1999.
13. Sudesh, S., Cohen, E.J., Rapuano, C.J., et al. Corneal toxicity associated with latanoprost. Arch. Ophthalmol. 117:539-540, 1999.
14. Ekatomatis, P. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br. J. Ophthalmol. 85:1008-1009, 2001.
15. Kroll, D.M., and Schuman, J.S. Reactivation of Herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am. J. Ophthalmol. 133:401-403, 2002.
16. Kaufman, H.H., Varnell, E.D., and Thompson, H.W. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am. J. Ophthalmol. 127:531-536, 1999.
17. Inglot, A.D., and Woyton, A. Topical treatment of cutaneous Herpes simplex in humans with the nonsteroid anti-inflammatory drugs: Mefenamic acid and indomethacin in dimethylsulfoxide. Archivum Immunologiae et Therapiae Experimentalis 19:555-566, 1971.
18. Wachsman, M., Aurelian, L., and Burnett, J.W. The prophylactic use of cyclo-oxygenase inhibitors in recurrent Herpes simplex infections. Br. J. Dermatol. 123:375-380, 1990.
19. Karádi, I., Kárpáti, S., and Romics, L. Aspirin in the management of recurrent Herpes simplex virus infection. Ann. Intern. Med. 128:696-697, 1998.
20. Newton, A.A. Effect of cyclic nucleotides on the response of cells to infection by various herpesviruses. In: deThe, G., Henle, W., and Rapp, F., eds. Oncogenesis and Herpes Viruses III. I.A.R.C., Lyon, France: 1978:381-387.
21. Newton, A.A. Inhibitors of prostaglandin synthesis as inhibitor of Herpes simplex virus replication. Adv. Ophthalmol. 38:58-63, 1979.
22. Newton, A.A. Prostaglandins and the replication of Herpes simplex type 1. In: Shiota, H., Cheng, Y.C., and Prusoff, W.H., eds. Herpesvirus: Clinical, Pharmacological and Basic Aspects. Excerpta Medica, Amsterdam, The Netherlands: 1982;192-200.
23. Hill, T.J., and Blyth, W.A. An alternative theory of herpes-simplex recurrence and a possible role for prostaglandins. Lancet 1:397-399, 1976.
24. Blyth, W.A., Hill, T.J., Field, H.J., et al. Reactivation of Herpes simplex virus infection by ultraviolet light and possible involvement of prostaglandins. J. Gen. Virol. 33:547-550, 1976.
25. Harbour, D.A., Blyth, W.A., and Hill, T.J. Prostaglandins enhance spread of Herpes simplex virus in cell cultures. J. Gen. Virol. 41:87-95, 1978.
26. Kurane, I., Tsuchiya, Y., Sekizawa, T., et al. Inhibition by indomethacin of in vitro reactivation of latent Herpes simplex virus type 1 in murine trigeminal ganglia. J. Gen. Virol. 65:1665-1674, 1984.
27. 2 in a rabbit model of herpetic keratitis. Antimicrob. Agents Chemother. 40:2327-2331, 1996.
28. Gordon, Y.J., Yates, K.A., Mah, F.S., et al. The effects of Xalatan® on the recovery of ocular Herpes simplex virus type 1 (HSV-1) in the induced reactivation and spontaneous shedding rabbit models. J. Ocul. Pharmacol. Ther. 19:233-245, 2003.
29. Collum, L.M.T., McGettrick, P., Akhtar, J., et al. Oral acyclovir (Zovirax) in Herpes simplex dendritic corneal ulceration. Br. J. Ophthalmol. 70:435-438, 1986.
30. Hoth, H.B., Hurley, C., Claoue, C., et al. Randomized trial of ganciclovir and acyclovir in the treatment of Herpes simplex dendritic keratitis: A multicenter study. Br. J. Ophthalmol. 80:140-143, 1996.
31. The Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent Herpes simplex virus eye disease. N. Engl. J. Med. 339:300-306, 1998.
32. Uchoa, U.B.C., Rezende, R.A., Carrasco, M.A., et al. Long-term acyclovir use to prevent recurrent ocular Herpes simplex virus infection. Arch. Ophthalmol. 121:1702-1704, 2003.
33. Hill, J.M., Lukiw, W.J., Gebhardt, B.M., et al. Gene expression analyzed by microarrays in HSV-1 latent mouse trigeminal ganglion following heat stress. Virus Genes 23:273-280, 2001.
34. Higaki, S., Gebhardt, B.M., Lukiw, W.J., et al. Gene expression profiling in the HSV-1 latently infected mouse trigeminal ganglia following hyperthermic stress. Curr. Eye Res. 26:231-238, 2003.
35. Gebhardt, B.M., Varnell, E.D., and Kaufman, H.E. Acetylsalicylic acid reduces viral shedding induced by thermal stress. Curr. Eye Res. 29:119-125, 2004.
36. Sawtell, N.M., and Thompson, R.L. Rapid in vivo reactivation of Herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J. Virol. 66:2150-2156, 1992.
37. Gebhardt, B.M., and Kaufman, H.E. Propranolol suppresses reactivation of herpesvirus. Antivir. Res. 27:255-261, 1995.
38. 2-phenylguanine (HBPG), a thymidine kinase inhibitor, suppresses herpes virus reactivation in mice. Antivir. Res. 30:87-94, 1996.
39. Spruance, S.L., Hamill, M.L., Hoge, W.S., et al. Acyclovir prevents reactivation of Herpes simplex labialis in skiers. JAMA 260:1597-1599, 1988.
40. Spruance, S.L., Freeman, D.J., Stewart, J.C.B., et al. The natural history of ultraviolet radiation-induced Herpes simplex labialis and response to therapy with per-oral and topical formulations of acyclovir. J. Infect. Dis. 163:728-734, 1991.
41. Rooney, J.F., Straus, S.E., Mannix, M.L., et al. Oral acyclovir to suppress frequently recurrent herpes labialis. Ann. Intern. Med. 118:268-272, 1993.
42. Wald, A., Zeh, J., Barnum, G., et al. Suppression of subclinical shedding of Herpes simplex virus type 2 with acyclovir. Ann. Intern. Med. 124:8-15, 1996.
43. Wutzler, P. Antiviral therapy of Herpes simplex and varicella-zoster virus infections. Intervirology 40:343-356, 1997.
44. Lipsitch, M., Bacon, T.H., Leary, J.J., et al. Effects of antiviral usage on transmission dynamics of Herpes simplex virus type 1 and on antiviral resistance: Predictions of mathematical models. Antimicrob. Agents Chemother. 44:2824-2835, 2000.
45. Corey, L., Wald, A., Patel, R., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 350:11-20, 2004.